The goal of this study was to determine if the apolipoprotein e gene, which is a well-established susceptibility factor for Alzheimer disease (AD) pathology in typical amnestic dementias, may also represent a risk factor in the language-based dementia, primary progressive aphasia (PPA). Apolipoprotein E genotyping was obtained from 149 patients with a clinical diagnosis of PPA, 330 cognitively healthy individuals (NC), and 179 patients with a clinical diagnosis of probable Alzheimer's disease (PrAD). Allele frequencies were compared among the groups. Analyses were also completed by sex and in 2 subsets of PPA patients: 1 in which the patients were classified by subtype (logopenic, agrammatic, and semantic) and another in which pathologic data were available. The allele frequencies for the PPA group (e2:5%, e3:79.5%, and e4:15.4%) showed a distribution similar to the NC group, but significantly different from the PrAD group. The presence of an e4 allele did not influence the age of symptom onset or aid in the prediction of AD pathology in PPA. These data show that e4 polymorphism, which is a well-known risk factor for AD pathology in typical amnestic dementias, has no similar relationship to the clinical syndrome of PPA or its association with AD pathology.
P rimary progressive aphasia (PPA) is a clinical neurodegenerative dementia syndrome characterized by a gradual dissolution of language but relative sparing of other cognitive domains (eg, memory, reasoning) during the initial stages of the disease. The diagnostic criteria (Table 1) 1 have been adopted by the Alzheimer's Disease Centers of the National Institute on Aging and implemented in the Uniform Data Set. 2 These criteria allow for the language-based dementia of PPA to be distinguished from the memory-based dementia of probable Alzheimer disease (PrAD a.k.a. Dementia of the Alzheimer Type, DAT) and the behavioral-based frontotemporal dementia (bvFTD) syndrome. Despite substantial progress in our understanding of PPA, little is known about the epidemiology and risk factors associated with this relatively rare dementia syndrome.
The apolipoprotein e (ApoE) gene is localized on chromosome 19 and has 3 common alleles (e2, e3, and e4), which determine 6 genotypes in the general population. It is thought to play a fundamental role in cell maintenance and repair through its function in lipid transport and cellular metabolism. 3 The e4 allele of this gene is a well-established susceptibility factor in AD and may influence the rate of progression in other neurologic disorders. [4] [5] [6] [7] [8] [9] However, the role of the e4 allele as a risk factor in the clinical syndrome of PPA is less clear. In 1997, Mesulam et al 10 found no association between the presence of the of an e4 allele in a group of 12 patients with a clinical diagnosis of PPA. This finding was supported in a report by Masullo et al 11 who examined patients with focal cortical atrophy, including individuals with a clinical diagnosis of PPA. In contrast, however, other studies suggest that the e4 allele may represent a risk factor in PPA. [12] [13] [14] Specifically, Acciarri et al 13 found an increased incidence of the e2/e4 genotype in 15 patients with PPA and Daniele et al 15 extended this finding by suggesting that the e2/e4 genotype may represent a significant risk factor for women. Common challenges that restrict the interpretation of these studies, are the relatively low number of patients (n<40) and the mixture of clinical phenotypes (eg, PPA, bvFTD, and focal cortical atrophy patients).
This study contributes additional information on ApoE allele and genotype distributions in a significantly larger sample of 149 patients with the clinical syndrome of PPA. These distributions were compared with those in a group of cognitively healthy controls and a group of individuals with a clinical amnestic dementia diagnosis. Analyses were also completed by sex and in 2 subsets of PPA patients: one in which patients were classified by subtype (logopenic, agrammatic, and semantic) and another in which pathologic data were available. Earlier studies have reported that up to 30% of patients with clinical PPA are found to have AD pathology at postmortem brain autopsy. Therefore, a subsequent analysis was also undertaken to determine if the presence of at least one e4 allele predicted AD pathology in the PPA group.
METHODS
Participants in the Clinical Core of the Northwestern Alzheimer's Disease Center registry (NADC), Chicago, IL, gave written informed consent and provided a blood sample, from which DNA was extracted for genotyping. ApoE genotyping was completed at Northwestern University following the method described by Hixson and Vernier. 16 In brief, this method includes the amplification of DNA by polymerase chain reaction in a thermal cycler. After polymerase chain reaction amplification, the resulting products were cut with a restriction enzyme and incubated overnight in a 371C oven. After incubation, the samples were run on a vertical electrophoresis device for several hours over polyacrylamide gels stained with ethidium bromide to highlight the bands of DNA. A CCD camera system was used to visualize the banding patterns. The banding patterns were then compared with the known ApoE control patterns that were run with each batch of samples to determine the genotype of each DNA product.
Inclusion criteria for this study required (1) ApoE genotype testing and (2) a clinical diagnosis of PrAD by established research diagnostic criteria, 17 PPA by published criteria 18, 19 or cognitively healthy normal control (NC) based on neuropsychologic test scores and informant report. All the participants in the NADC registry who met these criteria were included. The genotypes of the participants were not known before inclusion to avoid selection bias.The PrAD group was included because the clinical dementia profile differs from PPA and there is a well-known e4-risk profile. Using both a healthy and an atrisk population as comparison groups provides greater context for understanding the allele and genotype frequencies of the PPA group.
Information was available for 658 individuals. Of these, 330 were classified as NC, 179 as PrAD, and 149 as PPA. Clinical diagnoses were made by the consensus of a neurologist (including M.M.) and a neuropsychologist (including N.J. and S.W.) at the NADC. All patients with PPA in this sample shared the common feature of a salient aphasia with relative preservation of other cognitive domains. The demographic characteristics for the each of the groups (NC, PPA, and PrAD) are provided in Table 2 .
PPA has been divided into agrammatic (PPA-G), semantic (PPA-S), logopenic (PPA-L), and mixed (PPA-M) variants. 20, 21 Using the descriptive criteria provided by Mesulam et al 20 2 cohorts of patients with PPA were subtyped in this study: (1) a prospective cohort (n=31) of patients enrolled in a longitudinal project; and (2) a retrospective chart review of patients that had come to autopsy (n=31).
Statistical Analysis
The main analyses consist of the comparison of genotype or allele frequencies among diagnostic groups and between sex groups. For the comparison of genotypes, the person is the unit of analysis and these analyses were done using a w 2 test for a 2 Â2 table, yielding P values, odds ratios (ORs), and confidence intervals. For the comparison of allele frequencies, the allele is the unit of analysis and these comparisons were done using a generalized linear model taking into account the repeated measures because there are two alleles within person. Comparisons were completed for single genotypes or allele types between groups. For the comparisons with the control group, the control group is the reference category. For the comparison of PrAD with PPA, the PPA group is the reference category. ORs are defined as the odds of the genotype (or allele) in the group of interest versus the odds in the reference group. As the sex distributions differed between the PPA group and the comparison groups all comparisons were adjusted for age and sex. The association between number of ApoE alleles and age of onset was assessed using the Kruskal-Wallis test. A Fisher exact test was used to examine the relationship between the presence of an e4 allele and its association with AD neuropathology.
The w 2 goodness of fit test was used to compare observed genotype frequencies with Hardy-Weinberg expected frequencies.
RESULTS

Allele Frequency
The allele distributions for each group are reported in Table 3 . Results showed no significant differences in allele frequency between patients with PPA and controls (PZ0.66 for each comparison). The amnestic dementia group had significantly more e4 alleles than the PPA group [P<0.0001; OR: 0.27; 95% confidence interval (CI) 0.18 to 0.41], whereas the patients with PPA had more e3 alleles than the amnestic dementia group (P<0.0001; OR=2.89; CI: 1.96, 4.24). The e2 frequency did not differ between the PPA and PrAD groups (P=0.15), although allele sample was small in this comparison. As expected, individuals with a clinical diagnosis of PrAD also showed significant difference in allele counts from NC for each of the alleles (e2 P=0.02; OR: 0.46; CI: 0.24, 0.91; e3 P<0.0001; OR: 0.35; CI: 0.26, 0.46; e4 P< 0.0001; OR: 3.99; CI: 2.96, 5.39). Taken together the results suggest that the PPA and NC have similar allele distributions, whereas the amnestic dementia group has a unique allele profile.
Earlier studies suggest that the e4 allele frequencies may differ between PPA variants. 21 Subtyping information was available for a subset of 62 patients with PPA from our cohort and their allele frequencies are reported in Table 4 . The allele frequencies for each PPA subtype were compared with the allele frequencies of the NC group. Results from these analyses showed no significant differences in allele frequency between each PPA subtype and the NC frequencies (PZ0.05 for each comparison).
Genotype Frequency
The genotype distributions for each group are reported in Table 3 . Similar to the allele frequency results, there were no the differences in the frequencies of the 6 genotype comparisons between patients with PPA and NC (PZ0.41 for all 6 genotype comparisons). As expected, the patients with amnestic dementia showed a distinct genotype frequency profile from both PPA and NC groups ( Table 3) 
Allele and Genotype Distribution by Sex
Recent studies suggest that susceptibility factors may differ by sex in PPA. 15 The allele frequency analysis by sex and diagnosis (PPA and NC) did not show differences in allele frequency by sex in the PPA and control groups (PZ0.46 for each comparison). The genotype frequency analysis by sex also failed to show significant differences (PZ0.15 for each comparison). Table 1 for subtype descriptions).
Dose of e4 and Its Relationship to Age of Onset
Data from a earlier study examining an group of "frontal lobe dementia" patients indicated an inverse relationship with age of onset and the number of e4 alleles, such that, the age of onset decreased as the number of e4 alleles increased. 22 We completed a similar analysis to determine if this relationship was evident in our cohort of patients with PPA. The results failed to show a relationship between age of onset and the number of e4 alleles (P=0.43; median age of onset for zero e4 alleles=62.0, n=107; 1 e4 allele=64.0, n=38; 2 e4 alleles=64.5, n=4).
Neuropathology and e4
Neuropathology in postmortem brains of patients with PPA is mixed, with nearly 30% of patients with PPA showing plaques and tangles sufficient for the pathologic diagnosis of AD. One hypothesis is that PPA patients with e4 are more likely to have AD pathology. To investigate this hypothesis, we analyzed a subset of 31 patients who had come to autopsy with a clinical diagnosis of PPA and also had ApoE genotyping information available (see Table 5 in the supplementary material for information on the subset of PPA patients used in this analysis, See Suplemental Digital Content 1, http://links.lww.com/wad/A12). Results from the Fisher exact test showed no significant association between the presence of an e4 allele and the presence of AD pathology (P=0.71). Eleven patients had at least one e4 allele and 20 patients did not have an e4 allele. Sixty-four percent of the patients with at least one e4 allele had AD pathology, whereas 50% of the cases with no e4 alleles had AD pathology.
Hardy-Weinberg Equilibrium
For each diagnostic group, the allele frequencies were used to calculate expected Hardy-Weinberg genotype equilibrium probabilities. Goodness of fit tests indicated that the observed genotype frequencies fit the expected frequencies (P>0.99 for NC, PPA, and PrAD). For the autopsy cohort, using an average allele frequency across all the groups, the 35% occurrence of any e4 genotype fit Hardy-Weinberg expected values (P=0.64).
DISCUSSION
This study examined the frequency of the e4 allele and its combinatorial genotypes in patients with the clinical syndrome of PPA and compared them with frequencies in patients with the memory-based dementia of the Alzheimer type and in cognitively healthy controls. Findings showed that the ApoE allele distribution in PPA is significantly different from the group with a clinical diagnosis of PrAD and similar to that of the NC group. These data suggest that the e4 polymorphism, a well-known risk factor for the memory-based dementia and AD, has no similar relationship to the clinical syndrome of PPA. Furthermore, in the PPA group the e4 dose was not related to sex or age of symptom onset. In fact, the median age of onset was highest in patients with the two e4 alleles, in contrast to the tendency for earlier onset disease in patients with Alzheimer dementia and an e4 allele. However, only 4 patients had two e4 alleles making this finding difficult to interpret. It will be interesting to see if this relationship remains true in a larger sample. Finally, there was no relationship between the presence of an e4 allele and the postmortem neuropathology for those in whom those data were available.
Taken together, the results of this study suggest that the clinical syndrome of PPA and/or its pathologic etiology have no association relative to the ApoE genotype or allele distribution.
The conclusion that the e4 allele is not a risk factor in PPA is at odds with some studies, 12, 13, 15, 22 but in line with others, including one from this laboratory with a smaller number of participants. 10, 11 The differences between our findings and others may be attributable to the relatively small sample sizes in earlier studies. This study, while still limited in size in comparison with population based studies, has at least 3 times more patients than the earlier published reports on this topic.
The presence of an e4 allele did not increase the accuracy in predicting AD pathology in the 31 PPA with pathological diagnoses. Sixty-four percent of the patients with at least one e4 allele had AD pathology, whereas 50% of the cases with no e4 alleles had AD pathology. These observations highlight the differences in disease risk factors for the clinical aphasic versus amnestic dementia even at the pathologic level.
The ability to reliably predict the pathologic etiology of PPA continues to be a primary need, as accurate pathologic forecasting is critical for the development and, eventually, the delivery of treatment. Currently, there are no definitive in vivo biomarkers for the underlying pathologies, although postmortem series and in vivo amyloid imaging suggest that individual clinical variants of PPA have distinctive probabilities of being caused by AD pathology versus one of the several forms of frontotemporal lobar degeneration. [23] [24] [25] The are 3 readily recognized clinical variants of PPA, namely, PPA-G, PPA-S and PPA-L, which can be distinguished by their clinical and anatomic features 20 (Table 1 ). Earlier studies suggest that the PPA-L variant may be more likely to have AD pathology. [23] [24] [25] We addressed this issue using 2 cohorts of patients with PPA: (1) a cohort (n=62) of patients who had been classified by subtype; and (2) a subset of patients who had also come to autopsy (n=31). The first analysis compared allele frequencies of the NC group to each of the PPA subtypes and results showed allele frequencies for each subtype were not significantly different from the control cohort. Although not significant, the e4 allele was present more frequently in the PPA-L (20%) and PPA-S (21.4%) groups compared with the PPA-G (6.8%) group (Table 4 ). Nonetheless, the frequencies for each subtype were still lower than that of the PrAD (39.4%) group. The e4 allele frequency in our PPA-L group was also lower than that reported by Gorno-Tempini et al, 21 namely, 67% and Migliaccio et al 26 (55%). However, these observations were made in small sample sizes (n< 13 for each study) making a clear interpretation difficult. It will be important for future studies to be based on large sample sizes.
In our cohort with autopsy information, the likelihood of pathologic changes consistent with AD was more frequent in the PPA-L group 57% (8/14 patients) than the PPA-G group 20% (2/10 patients), which is consistent with the earlier literature. However, the e4 allele frequency was not elevated in the PPA-L group, suggesting that the presence of an e4 allele does not offer additional predictive value.
In summary, the results show that the ApoE allele and genotype distribution in PPA is significantly different from the one observed in PrAD and comparable with that of a nondemented older control population. Although this is the largest study of ApoE distribution in PPA, it is still a relatively small group and larger prospective studies incorporating subtype classification and pathologic characterization are needed.
In addition to their practical implications for predicting the nature of the underlying pathology, these results also have implications for understanding the molecular basis of selective vulnerability patterns. One possible interpretation is that the e4 allele may be a risk factor specifically for the type of amyloid and tangle pathology that selectively targets the hippocampo-entorhinal complex and that leads to the typical amnestic phenotype. Another more speculative interpretation is that AD pathology in PPA may not reflect the causative mechanism for the aphasic phenotype and that we may need to look further for alternative neuropathologic processes that may have triggered the initial aphasic phenotype but that may have been obscured, 10 to 15 years after onset, by the secondary or age-related emergence of plaques and tangles. Further support for the contention that ApoE may differentially influence different neurodegenerative diseases comes from Agosta et al 14 who showed that the presence of an e4 allele influences both disease risk and brain atrophy in AD but only brain atrophy in bvFTD. At the epidemiologic level, the results from this study show that the clinical diagnosis of aphasic versus amnestic dementia reflect 2 different genetic pools with respect to disease risk factors.
